PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27658195-7	2016	Additionally, IL-17A inhibition in mice using digoxin or SR1001, showed therapeutic promise in limiting parasite virulence.	Digoxin	46-53	interleukin 17A	Mus musculus	14-20	
33859430-3	2021	Here, we demonstrate that abolishing the interleukin-17A (IL-17A) axis in mice by inhibition of RORgammat-mediated IL-17A production by digoxin, or by ubiquitous deletion of IL-17 receptor A (Il17ra), suppresses diet-induced obesity (DIO) and metabolic disorders, and promotes adipose-tissue browning, thermogenesis and energy expenditure.	Digoxin	136-143	interleukin 17A	Mus musculus	58-64	
35498227-5	2022	Digoxin"s ameliorative effect on DN-hepatotoxicity coincided with (i) lowering the increased hepatic production and release of the proinflammatory mediators IL-17A, IL-1beta and TNF-alpha, and (ii) impeding the attraction and infiltration of monocytes to the liver, as denoted by decreasing serum MCP-1 and F4/80 immunohistochemical expression.	Digoxin	0-7	interleukin 17A	Mus musculus	157-163	
29545199-4	2018	The cardiac glycoside digoxin inhibits the master transcription factor of T helper 17 differentiation, retinoid acid receptor-related orphan nuclear receptor gammat, and attenuates IL-17-dependent pathologies in mice.	Digoxin	22-29	interleukin 17A	Mus musculus	181-186	
26879387-7	2016	Moreover, treatment with digoxin markedly attenuated IL-17A expression and IL-17A-related inflammatory responses and increased the abundance of regulatory T cells (Tregs).	Digoxin	25-32	interleukin 17A	Mus musculus	53-59	
26879387-7	2016	Moreover, treatment with digoxin markedly attenuated IL-17A expression and IL-17A-related inflammatory responses and increased the abundance of regulatory T cells (Tregs).	Digoxin	25-32	interleukin 17A	Mus musculus	75-81	
26879387-8	2016	CONCLUSIONS AND IMPLICATIONS: Our data demonstrate that digoxin acts as a specific antagonist of retinoid-related orphan receptor-gamma to decrease atherosclerosis by suppressing lipid levels and IL-17A-related inflammatory responses.	Digoxin	56-63	interleukin 17A	Mus musculus	196-202	
25234817-0	2014	Inhibiting the Th17/IL-17A-related inflammatory responses with digoxin confers protection against experimental abdominal aortic aneurysm.	Digoxin	63-70	interleukin 17A	Mus musculus	20-26	
25819229-6	2015	The expression of IL-17 and other proinflammatory cytokines, including IL-1beta, IL-6, TNF-alpha and IL-21, were markedly reduced in the arthritic joints of digoxin-treated CIA mice.	Digoxin	157-164	interleukin 17A	Mus musculus	18-23	
25819229-8	2015	The mRNA expression of IL-17 and ROR gammat was consistently lower in total splenocytes or draining lymph node cells obtained from digoxin-treated CIA mice.	Digoxin	131-138	interleukin 17A	Mus musculus	23-28	
25234817-10	2014	The T helper 17- and interleukin-17A-related inflammatory responses were dose-dependently attenuated by digoxin treatment.	Digoxin	104-111	interleukin 17A	Mus musculus	21-36	
23813495-6	2014	Inhibition of Th17 differentiation by digoxin lowered Th17 marker gene expression and IL-17 production and strongly reduced liver fibrosis in CB2(-/-) BDL mice.	Digoxin	38-45	interleukin 17A	Mus musculus	86-91	
21733845-0	2011	Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production.	Digoxin	20-27	interleukin 17A	Mus musculus	119-138	
21733845-2	2011	To develop a therapeutic agent against Th17-mediated autoimmune diseases, we screened chemical compounds and successfully found that digoxin inhibited IL-17 production.	Digoxin	133-140	interleukin 17A	Mus musculus	151-156	
21733845-7	2011	Functional studies demonstrated that digoxin inhibited RORgammat activity and decreased IL-17 production but not RORalpha activity.	Digoxin	37-44	interleukin 17A	Mus musculus	88-93	
21733845-8	2011	Digoxin inhibited IL-17 production in CD4(+) T cells from experimental autoimmune encephalomyelitis mice.	Digoxin	0-7	interleukin 17A	Mus musculus	18-23